In this issue:
Breast cancer risk after anthracyclines for childhood cancer
Deep learning radiopathomics for differentiating luminal from nonluminal early-stage breast cancer
Amcenestrant in oestrogen receptor+, HER2– advanced breast cancer
Impact of occult lymph node involvement in small HER2+ early breast cancer treated surgically
Neoadjuvant palbociclib + giredestrant or anastrozole in oestrogen receptor+, HER2– early breast cancer
Nivolumab, abemaciclib + endocrine therapy in hormone receptor+, HER2– metastatic breast cancer
Outcomes after permissive cardiotoxicity in trastuzumab recipients
Endocrine therapy ± ribociclib in progressive hormone receptor+, HER2– metastatic breast cancer on CDK4/6 inhibitors
Letrozole’s effects on oestradiol/oestrone levels in postmenopausal breast cancer
Pertuzumab and ado-trastuzumab emtansine for breast cancer: recurrence projections
Please login below to download this issue (PDF)